What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer скачать в хорошем качестве

What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer

What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer CME Available: https://auau.auanet.org/node/29347 Upon completion of this activity, participants will be able to: 1. List the three main advanced prostate cancer disease states (HSMPC); M0 CRPC and M1 CRPC) and be able to identify these patients in urologic practice. 2. Identify FDA-hormonal and non-hormonal therapies for use in each of these three disease states: HSMPC, M0 CRPC, M1 CRPC. 3. Demonstrate the safe use and unique mechanism of action and side effects of new and existing agents. 4. Explain the sequencing of novel therapies and be able to identify patient progression of disease by PSA, imaging and signs and symptoms. 5. Work in team care including urologists, advanced practice providers, oncology nursing, oncology pharmacy, medical oncology and radiation oncology and their support staffs. This educational activity is supported by independent educational grants from: Astellas AstraZeneca Bristol-Myers Squibb Genentech Merck Pfizer, Inc. Sanofi Genzyme